Alnylam Pharmaceuticals (ALNY) News Today $284.68 -5.42 (-1.87%) As of 09:33 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALNY Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period California State Teachers Retirement System Acquires 5,037 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)California State Teachers Retirement System lifted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 2.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 196,362 shares of the biopharmMay 29 at 7:41 AM | marketbeat.comBannerman Wealth Management Group LLC Acquires Shares of 1,391 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Bannerman Wealth Management Group LLC acquired a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 1,391 shares of the biopharmaceuticalMay 29 at 6:13 AM | marketbeat.comVoloridge Investment Management LLC Has $3.95 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Voloridge Investment Management LLC cut its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 91.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,776 shares of the biopharmaceutiMay 29 at 4:29 AM | marketbeat.comAlnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare ConferenceMay 29 at 2:54 AM | finance.yahoo.comAre Brighter Days Ahead for This Fidelity Health Care Fund?May 28 at 12:47 AM | msn.comBiogen partners with John Maraganore’s new RNAi startupMay 27 at 7:46 PM | bizjournals.comGF Fund Management CO. LTD. Takes $637,000 Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)GF Fund Management CO. LTD. bought a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 2,708 shares of the biopharmaceutMay 27 at 5:14 AM | marketbeat.comPublic Employees Retirement System of Ohio Has $10.41 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Public Employees Retirement System of Ohio lessened its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 8.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 44,257 shares of the biopharmaceutical company's stockMay 27 at 4:57 AM | marketbeat.comHere's How Much $1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth TodayMay 26 at 11:24 PM | benzinga.comAlnylam supports LGBT community inside and outside the workplaceMay 26 at 8:21 AM | bizjournals.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by USS Investment Management LtdUSS Investment Management Ltd decreased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 19.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 26,366 shares of the bioMay 25, 2025 | marketbeat.comQuantinno Capital Management LP Purchases 1,190 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Quantinno Capital Management LP raised its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 35.4% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 4,556 shares of the biopharmaceMay 25, 2025 | marketbeat.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Purchased by Cetera Investment AdvisersCetera Investment Advisers increased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 66.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,770 shares of the biopharmaMay 25, 2025 | marketbeat.com3 High-Flying Stocks That Could Soar Even MoreMay 24, 2025 | fool.comTwo Sigma Advisers LP Has $18.54 Million Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Two Sigma Advisers LP cut its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 23.6% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 78,800 shares of the biopharmaceutical company's stock after selling 2May 24, 2025 | marketbeat.comTwo Sigma Investments LP Purchases 87,969 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Two Sigma Investments LP grew its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 459.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 107,117 shares of the biopharmaceutical company's stock after acquiring aMay 24, 2025 | marketbeat.comTidal Investments LLC Lowers Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Tidal Investments LLC cut its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 35.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,188 shares of the biopharmaceutical coMay 24, 2025 | marketbeat.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by ProShare Advisors LLCProShare Advisors LLC cut its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 19.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,110 shares of thMay 24, 2025 | marketbeat.comWorldquant Millennium Advisors LLC Raises Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Worldquant Millennium Advisors LLC boosted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 156.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 150,191 shares of the biopharmaceutical comMay 23, 2025 | marketbeat.comZurich Insurance Group Ltd FI Makes New Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Zurich Insurance Group Ltd FI purchased a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 27,977 shares of the biopMay 23, 2025 | marketbeat.comSilvercrest Asset Management Group LLC Purchases Shares of 4,891 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Silvercrest Asset Management Group LLC purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 4,891 shares of the biopharmaceutical companMay 23, 2025 | marketbeat.comMIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Sells 11,081 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lessened its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 42.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,731 shares of thMay 22, 2025 | marketbeat.comThe Play On BridgeBio Pharma: Great Expectations For AttrubyMay 21, 2025 | seekingalpha.comAlnylam Issues 2024 Corporate Responsibility ReportMay 21, 2025 | uk.finance.yahoo.comSoleus Capital Management L.P. Acquires 17,400 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Soleus Capital Management L.P. grew its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 29.3% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 76,800 shares of the biopharmaceutical company's stock after buying an aMay 21, 2025 | marketbeat.com16,323 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Acquired by Tema Etfs LLCTema Etfs LLC purchased a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 16,323 shares of the biopharmaceutical company's sMay 20, 2025 | marketbeat.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Acquired by Siemens Fonds Invest GmbHSiemens Fonds Invest GmbH grew its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 137.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,245 shares of the biopharmaceutical company's stock afteMay 20, 2025 | marketbeat.comFocus Partners Wealth Purchases 3,144 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Focus Partners Wealth boosted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 245.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,427 shares of the biopharmaceutical company's stock afteMay 20, 2025 | marketbeat.comRafferty Asset Management LLC Sells 11,014 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Rafferty Asset Management LLC reduced its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 17.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 52,817 shares of the biopharmaceutical company's stock after selling 11,014 sharesMay 19, 2025 | marketbeat.comOMERS ADMINISTRATION Corp Purchases 891 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)OMERS ADMINISTRATION Corp boosted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 20.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,252 shares of the biopharmaceutical comMay 19, 2025 | marketbeat.comAlnylam presents contemporary analysis of HELIOS-B Phase 3 study of vutrisiranMay 18, 2025 | msn.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Position Trimmed by Gotham Asset Management LLCGotham Asset Management LLC decreased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 37.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 10,924 shares of the biophaMay 18, 2025 | marketbeat.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Graham Capital Management L.P.Graham Capital Management L.P. decreased its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 34.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owMay 18, 2025 | marketbeat.comAlnylam Pharmaceuticals' Vutrisiran Shows Promising Results in Phase 3 Study for ATTR-CM | ALNY ...May 17, 2025 | gurufocus.comAlnylam posts new Phase 3 data for heart disease therapy AmvuttraMay 17, 2025 | msn.comAMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-BMay 17, 2025 | businesswire.comHigh Growth US Tech Stocks To Watch In May 2025May 16, 2025 | finance.yahoo.comParkman Healthcare Partners LLC Has $9.10 Million Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Parkman Healthcare Partners LLC raised its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 51.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 38,672 shares of the biophMay 16, 2025 | marketbeat.comLMR Partners LLP Has $2.80 Million Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)LMR Partners LLP reduced its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 82.4% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 11,901 shares of the biopharmaceutical company's stock after selling 55,588 sharesMay 16, 2025 | marketbeat.comJanus Henderson Group PLC Sells 9,257 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Janus Henderson Group PLC reduced its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 4.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 210,08May 16, 2025 | marketbeat.comCaptrust Financial Advisors Has $1.51 Million Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Captrust Financial Advisors boosted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 32.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,414 shares of the bioMay 16, 2025 | marketbeat.comOrbimed Advisors LLC Acquires 165,300 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Orbimed Advisors LLC increased its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 66.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 415,600 shares of the biopharmaceutical compMay 15, 2025 | marketbeat.comIntegral Health Asset Management LLC Purchases 20,000 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Integral Health Asset Management LLC boosted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 80.0% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 45,000 shares of the biopharmaceutical company's stockMay 14, 2025 | marketbeat.comEnsign Peak Advisors Inc Lowers Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Ensign Peak Advisors Inc lowered its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 5.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 76,464 shares of the biopharmaceutical companMay 14, 2025 | marketbeat.comAlnylam Pharmaceuticals, Inc. (ALNY): Among the Best Growth Stocks to Buy and Hold for the Long TermMay 13, 2025 | insidermonkey.com2,600 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Bought by Mercer Global Advisors Inc. ADVMercer Global Advisors Inc. ADV purchased a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 2,600 shares of the biopharmaceuticalMay 13, 2025 | marketbeat.comAlnylam Pharmaceuticals (NasdaqGS:ALNY) To Present Pivotal TTR Franchise Data At Heart Failure CongressMay 12, 2025 | finance.yahoo.comAlnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 CongressMay 12, 2025 | businesswire.comDriehaus Capital Management LLC Acquires 1,130 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Driehaus Capital Management LLC lifted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 3.5% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 33,480 shares of the biopharmaceutical company's stockMay 12, 2025 | marketbeat.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) has earned an average rating of "Moderate Buy" from the twenty-six ratings firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have given a holdMay 12, 2025 | marketbeat.com Get Alnylam Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter. Email Address ALNY Media Mentions By Week ALNY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALNY News Sentiment▼1.370.87▲Average Medical News Sentiment ALNY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALNY Articles This Week▼2215▲ALNY Articles Average Week Get Alnylam Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Amgen News Gilead Sciences News Vertex Pharmaceuticals News Regeneron Pharmaceuticals News Biogen News United Therapeutics News Incyte News Neurocrine Biosciences News Exelixis News BioMarin Pharmaceutical News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALNY) was last updated on 5/29/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alnylam Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.